Disease‐modifying treatments for multiple sclerosis–a review of approved medications Ø Torkildsen, KM Myhr, L Bø European journal of neurology 23, 18-27, 2016 | 382 | 2016 |
Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ... Multiple Sclerosis Journal 21 (8), 1013-1024, 2015 | 375 | 2015 |
The cuprizone model for demyelination Ø Torkildsen, LA Brunborg, KM Myhr, L Bø Acta neurologica scandinavica 117, 72-76, 2008 | 369 | 2008 |
Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation Y Xiao, J Jin, M Chang, JH Chang, H Hu, X Zhou, GC Brittain, ... Nature medicine 19 (5), 595-602, 2013 | 196 | 2013 |
Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation A Lossius, JN Johansen, Ø Torkildsen, F Vartdal, T Holmøy Viruses 4 (12), 3701-3730, 2012 | 182 | 2012 |
Neurofilament light chain as a biomarker in multiple sclerosis KN Varhaug, Ø Torkildsen, KM Myhr, CA Vedeler Frontiers in neurology 10, 338, 2019 | 170 | 2019 |
ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial Ø Torkildsen, S Wergeland, S Bakke, AG Beiske, KS Bjerve, H Hovdal, ... Archives of neurology 69 (8), 1044-1051, 2012 | 167 | 2012 |
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome G Disanto, R Adiutori, R Dobson, V Martinelli, G Dalla Costa, T Runia, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (2), 126-129, 2016 | 160 | 2016 |
Neurofilament light chain predicts disease activity in relapsing-remitting MS KN Varhaug, C Barro, K Bjørnevik, KM Myhr, Ø Torkildsen, S Wergeland, ... Neurology: Neuroimmunology & Neuroinflammation 5 (1), e422, 2017 | 153 | 2017 |
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment KI Løken-Amsrud, T Holmøy, SJ Bakke, AG Beiske, KS Bjerve, ... Neurology 79 (3), 267-273, 2012 | 153 | 2012 |
Time trends in the incidence and prevalence of multiple sclerosis in N orway during eight decades N Grytten, Ø Torkildsen, KM Myhr Acta Neurologica Scandinavica 132, 29-36, 2015 | 117 | 2015 |
Dietary vitamin D3 supplements reduce demyelination in the cuprizone model S Wergeland, Ø Torkildsen, KM Myhr, L Aksnes, SJ Mørk, L Bø PloS one 6 (10), e26262, 2011 | 110 | 2011 |
Upregulation of immunoglobulin‐related genes in cortical sections from multiple sclerosis patients Ø Torkildsen, C Stansberg, SM Angelskår, EJ Kooi, JJG Geurts, ... Brain Pathology 20 (4), 720-729, 2010 | 100 | 2010 |
Glitazone use associated with reduced risk of Parkinson's disease B Brakedal, I Flønes, SF Reiter, Ø Torkildsen, C Dölle, J Assmus, ... Movement Disorders 32 (11), 1594-1599, 2017 | 97 | 2017 |
An update on vitamin D and disease activity in multiple sclerosis J Smolders, Ø Torkildsen, W Camu, T Holmøy CNS drugs 33, 1187-1199, 2019 | 93 | 2019 |
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis S Kvistad, KM Myhr, T Holmøy, S Bakke, AG Beiske, KS Bjerve, H Hovdal, ... Multiple Sclerosis Journal 20 (14), 1833-1840, 2014 | 85 | 2014 |
Month of birth as a risk factor for multiple sclerosis: an update Ø Torkildsen, N Grytten, J Aarseth, KM Myhr, MT Kampman Acta Neurologica Scandinavica 126, 58-62, 2012 | 79 | 2012 |
International consensus on quality standards for brain health-focused care in multiple sclerosis J Hobart, A Bowen, G Pepper, H Crofts, L Eberhard, T Berger, A Boyko, ... Multiple Sclerosis Journal 25 (13), 1809-1818, 2019 | 77 | 2019 |
Vitamin D–dependent rickets as a possible risk factor for multiple sclerosis Ø Torkildsen, PM Knappskog, HI Nyland, KM Myhr Archives of neurology 65 (6), 809-811, 2008 | 77 | 2008 |
Selective processing of linguistic and pictorial food stimuli in females with anorexia and bulimia nervosa KM Stormark, Ø Torkildsen Eating behaviors 5 (1), 27-33, 2004 | 76 | 2004 |